Familial cancer syndromes

A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB.

ESMO gastrointestinal oncology·2026

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

ESMO open·2025

Can We Miniaturize CT Technology for a Successful Mobile Stroke Unit Roll-Out?

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2023

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022.

ESMO open·2023

Applying Mendelian randomization to appraise causality in relationships between smoking, depression and inflammation.

Scientific reports·2022

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Multifactorial Chylomicronemia Syndrome With a Rare APOA5 Variant and Recurrent Acute Pancreatitis: A Case Report From Rural Colombia.

Cureus·2026

Culturally Meaningful End-of-Life Care for a Patient With Cancer of Unknown Primary, and Severe Motor and Intellectual Disabilities: A Case Report.

Cureus·2026

The glioblastoma ecosystem: clonal evolution, heterogeneity, and therapeutic resistance.

Frontiers in cell and developmental biology·2026

Harnessing AI-driven approaches for detecting metabolic dysfunction-associated steatotic liver disease, assessing fibrosis, and stratifying hepatocellular carcinoma risk: a scoping review.

Frontiers in oncology·2026

The gut microbiota in colorectal cancer: role in cytokine regulation, intestinal immune barrier dysfunction.

Frontiers in oncology·2026

The role and application prospects of glycolysis-related non-coding RNAs in lung cancer.

Journal of translational medicine·2026

Related Experiment Videos

Familial cancer syndromes

Related Concept Videos

A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3.

Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB.

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

Can We Miniaturize CT Technology for a Successful Mobile Stroke Unit Roll-Out?

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022.

Applying Mendelian randomization to appraise causality in relationships between smoking, depression and inflammation.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Multifactorial Chylomicronemia Syndrome With a Rare APOA5 Variant and Recurrent Acute Pancreatitis: A Case Report From Rural Colombia.

Culturally Meaningful End-of-Life Care for a Patient With Cancer of Unknown Primary, and Severe Motor and Intellectual Disabilities: A Case Report.

The glioblastoma ecosystem: clonal evolution, heterogeneity, and therapeutic resistance.

Harnessing AI-driven approaches for detecting metabolic dysfunction-associated steatotic liver disease, assessing fibrosis, and stratifying hepatocellular carcinoma risk: a scoping review.

The gut microbiota in colorectal cancer: role in cytokine regulation, intestinal immune barrier dysfunction.

The role and application prospects of glycolysis-related non-coding RNAs in lung cancer.

Related Experiment Videos

Familial cancer syndromes

Related Concept Videos

Related Articles